Perth, Western Australia, 12 July 2019: Proteolytics Pty Ltd, a clinical-stage biotechnology company developing novel therapeutics for advanced wound care and skin disorders, today announced that initial results from an evaluation of the Company’s botanical pawpaw extract (OPAL-A) for the treatment of horses with hard-to heal wounds have been successful.
Proteolytics Announces First Data from Treatment of Horses with OPAL-A
Proteolytics Collaborates with University of Florida to Advance ProteoActiv™ Technology
05 July 2019
Proteolytics Announces First Data from Treatment of Skin Irritation with OPAL-A Pawpaw Extract
22 July 2019